查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1863442

多癌種篩檢市場按檢測類型、癌症類型、技術、支付方式、應用和最終用戶分類－2025-2032年全球預測

Multicancer Screening Market by Test Type, Cancer Type, Technology, Payment Source, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，多癌種篩檢市場將成長至 33.6 億美元，複合年成長率為 10.31%。

關鍵市場統計數據
基準年 2024 15.3億美元
預計年份：2025年 16.7億美元
預測年份 2032 33.6億美元
複合年成長率 (%) 10.31%

本文全面概述了多癌種篩檢的進步如何改變臨床實踐、研究重點以及診斷和治療路徑中的相關人員合作。

分子生物學、生物資訊學和檢體採集技術的進步正匯聚一堂，推動多癌種篩檢領域從實驗階段走向臨床和研究的實際應用。新的診斷方法正在重塑檢測模式，從微創檢體到更廣泛的組織覆蓋，從而改變臨床工作流程和患者診療路徑。因此，診斷開發、醫療服務和政策制定領域的利益相關人員正在重新評估早期檢測、長期監測和循證醫學證據產生的優先事項，以支持臨床應用。

臨床實驗室和研發人員正面臨來自科學和營運兩方面的壓力：既要平衡分析靈敏度和特異性，也要兼顧通量、成本和監管合規性。同時，支付方和醫療系統也要求提供明確的臨床效用證據，以及將積極發現融入臨床觀察的可行路徑。在此背景下，轉化研究和務實的臨床試驗正成為生物標記發現與常規應用之間的關鍵橋樑，有助於明確合適的應用場景、轉診網路和路徑經濟性，從而實現負責任的規模化應用。因此，現在就投資於可靠的臨床檢驗、互通性和相關人員協作的機構，有望加速可靠應用並產生長期影響。

技術、臨床和支付方的發展趨勢相互交匯，重新定義了多癌症種篩檢創新技術的研發重點和推廣路徑。

技術變革、數據整合以及報銷理念的轉變正在顛覆整個多篩檢格局。在技​​術層面，液態生物檢體、高通量定序和多重檢測的創新正在拓展可檢測分析物的範圍，並降低非侵入性取樣的門檻。這些技術進步伴隨著生物資訊學流程的改進，提高了訊號檢測的準確性，降低了假陽性噪聲，從而能夠提供更多具有臨床指導意義的結果。

在系統層面，醫療模式正朝著整合式醫療模式轉變，將篩檢結果與標準化的診斷追蹤和治療路徑連結起來。這種整合得益於可互通的數據標準和電子健康記錄的互聯互通，使篩檢結果能夠及時驅動臨床回應。同時，支付方的討論也從單一疾病檢測的單一報銷模式，轉向以價值為導向的框架，該框架考慮長期效益和後續的醫療協調。因此，相關人員在調整產品開發策略、臨床證據計畫和商業化藍圖，以適應這些變革，並確保臨床和商業性路徑的永續。

評估美國關稅政策波動如何影響診斷相關人員的供應鏈韌性、籌資策略和製造在地化決策。

關稅政策變化和貿易行動將對用於多癌種篩檢的試劑、儀器和客製化檢測組件的全球供應鏈產生重大影響。在美國，關稅制度的變化會影響定序試劑、質譜耗材和專用硬體等關鍵材料的到岸成本，進而影響實驗室和診斷開發人員的採購策略。這些成本壓力促使他們更加重視國內採購、策略供應商合作以及庫存管理技術，以維持檢測服務的連續性。

除了成本影響外，關稅正在加速策略性製造地決策和關鍵流程的在地化，促使企業考慮地理分散式供應鏈和近岸外包方案。風險緩解策略正推動一些機構增加對國內契約製造的投資，簽訂分包協議，並加強供應商資格認證計畫。同時，採購部門和實驗室營運人員正在加強情境規劃，以應對短期價格波動，同時確保檢測效能和合規性。最終，關稅政策的變化既是對營運的壓力測試，也是推動供應鏈韌性策略與長期臨床服務目標一致的促進者。

綜合細分分析揭示了檢測類型、癌症標靶、技術、支付方式、應用和最終用戶如何共同影響檢測的普及和臨床效用。

細分分析突顯了技術方法、臨床標靶、支付模式和終端用戶在多篩檢路徑中的多樣性。按檢測類型分類，目前的服務產品涵蓋範圍廣泛，從針對特定基因組區域的基因panel檢測，到經認證實驗室客製化的實驗室自建檢測（LDT），再到液態生物檢體領域也十分多樣，包括乳癌和大腸癌等成熟標靶，白血病等骨髓惡性腫瘤，肺癌等高負擔疾病，以及廣泛的特異性多器官癌症檢測模式，還有攝護腺癌等篩檢特異性標靶。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 人工智慧驅動的液態生物檢體檢測在多種癌症早期檢測中的應用日益廣泛
  • 監管核准流程影響下一代多癌症篩檢測試的商業化進程
  • 增加對cfDNA甲基化檢測板的投資正在提高檢測的靈敏度和特異性。
  • 透過診斷實驗室與科技公司之間的合作，加速多癌種篩檢創新
  • 消費者多癌種篩檢套件的廣泛普及，使得在家檢體樣本即可進行早期診斷。
  • 整合電子健康記錄數據和篩檢結果，以支持個人化癌症風險模型
  • 基於價值的報銷模式的出現正在影響醫療系統中多種癌症篩檢的普及。
  • 重點關注醫療服務不足的人群，以促進在低收入地區開展便利的多癌種篩檢計畫。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 按檢測類型分類的多癌種篩檢市場

  • 基因檢測
  • 實驗室自建測試
  • 液態生物檢體

第9章 依癌症類型分類的多癌症種篩檢市場

  • 乳癌
  • 大腸直腸癌
  • 白血病
  • 肺癌
  • 特異性多重器官癌
  • 攝護腺癌

第10章 以科技分類的多癌症種篩檢市場

  • 質譜分析
  • 微陣列
  • 次世代定序
  • 聚合酵素鏈鎖反應

11. 依支付方式分類的多癌種篩檢市場

  • 政府補貼
  • 自費
  • 私人醫療保險

第12章 多癌種篩檢市場（依應用領域分類）

  • 診斷篩檢
    • 早期檢測
    • 風險評估
  • 預後
    • 病患監測
    • 治療方法方案
    • 治療效果評估
  • 研究用途
    • 生物標記發現
    • 基因研究

第13章 依最終用戶分類的多癌症種篩檢市場

  • 門診手術中心
  • 診斷中心
  • 醫院
  • 研究所
  • 專科診所

第14章 各地區多元癌症篩檢市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 依組別分類的多癌症種篩檢市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國多癌症種篩檢市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • ANPAC Bio-Medical Science Co., Ltd.
    • Burning Rock Biotech Limited
    • Caris Life Sciences
    • Coyne Medical Ltd.
    • Delfi Diagnostics, Inc.
    • Elypta AB
    • EpiCypher, Inc.
    • Epigenomics AG
    • Exact Sciences Corporation
    • Foundation Medicine, Inc.
    • Freenome Holdings, Inc.
    • Fulgent Genetics, Inc.
    • Gene Solutions
    • Grail, LLC by Illumina, Inc.
    • Guangzhou AnchorDx Medical Co., Ltd.
    • Guardant Health, Inc.
    • Invitae Corporation
    • Laboratory Corporation of America Holdings
    • Lucence Health Inc.
    • Micronoma, Inc.
    • MiRXES Pte Ltd.
    • Myriad Genetics, Inc.
    • Natera, Inc.
    • Naveris, Inc.
    • NeoGenomics Laboratories
    • OneTest
    • Siemens Healthineers AG
    • StageZero Life Sciences. Ltd.
Product Code: MRR-5C6F41F5AFE7

The Multicancer Screening Market is projected to grow by USD 3.36 billion at a CAGR of 10.31% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.53 billion
Estimated Year [2025] USD 1.67 billion
Forecast Year [2032] USD 3.36 billion
CAGR (%) 10.31%

A compelling overview of how multicancer screening advances are shifting clinical practice, research priorities, and stakeholder collaboration across diagnostics and care pathways

The field of multicancer screening is evolving from experimental promise to pragmatic integration within clinical and research settings, driven by converging advances in molecular biology, bioinformatics, and sample collection technologies. Emerging diagnostic modalities are reframing detection paradigms by offering broader tissue coverage from minimally invasive samples, thereby reshaping clinical workflows and patient pathways. As a result, stakeholders across diagnostics development, healthcare delivery, and policy are reevaluating priorities around early detection, longitudinal monitoring, and evidence generation to sustain clinical adoption.

Clinical laboratories and developers are responding to both scientific and operational pressures: they must balance analytical sensitivity and specificity with throughput, cost, and regulatory compliance. Concurrently, payers and health systems are seeking clearer proof of clinical utility and actionable pathways to integrate positive findings into care. In this environment, translational research and pragmatic trials are emerging as critical bridges between biomarker discovery and routine use, helping to define appropriate use cases, referral networks, and pathway economics that enable responsible scale-up. Consequently, organizations that invest now in robust clinical validation, interoperability, and stakeholder alignment stand to accelerate credible adoption and long-term impact.

How converging technological, clinical, and payer evolutions are redefining development priorities and adoption pathways in multicancer screening innovation

Transformations in technology, data integration, and reimbursement thinking are producing a set of disruptive shifts across the multicancer screening landscape. On the technology front, innovations in liquid biopsy, high-throughput sequencing, and multiplexed assays are expanding the range of detectable analytes and lowering the barrier to noninvasive sampling. These technical gains are accompanied by enhanced bioinformatic pipelines that improve signal detection and reduce false positive noise, enabling more clinically actionable outputs.

At the systems level, there is a move toward integrated care models that link screening results to standardized diagnostic follow-up and treatment pathways. This integration is facilitated by interoperable data standards and electronic health record connectivity that allow screening outcomes to trigger timely clinical responses. Simultaneously, payer discussions are evolving from unitary reimbursement for single-disease tests toward value frameworks that consider longitudinal benefit and downstream care coordination. As a result, stakeholders are recalibrating product development strategies, clinical evidence plans, and commercialization roadmaps to align with these transformative shifts and to secure sustainable clinical and commercial pathways.

Assessing how shifting US tariff policies are influencing supply chain resilience, procurement strategies, and manufacturing localization decisions for diagnostic stakeholders

Tariff policy changes and trade measures can exert meaningful influence on global supply chains for reagents, instruments, and bespoke assay components used in multicancer screening. In the United States, shifts in tariff regimes affect the landed cost of critical inputs such as sequencing reagents, mass spectrometry consumables, and specialized hardware, which in turn influence procurement preferences among laboratories and diagnostic developers. These cost pressures encourage greater attention to domestic sourcing, strategic supplier partnerships, and inventory management practices to maintain continuity of testing services.

Beyond cost considerations, tariffs can accelerate strategic decisions about manufacturing footprint and localization of critical production steps, prompting firms to evaluate regionalized supply chains and nearshoring options. For some organizations, this translates into increased investments in domestic contract manufacturing, secondary sourcing contracts, and supplier qualification programs to mitigate exposure. In parallel, procurement teams and laboratory operators are intensifying scenario planning to absorb short-term pricing volatility while preserving assay performance and regulatory compliance. Ultimately, tariff dynamics serve as both an operational stress test and a catalyst for supply chain resilience strategies that align with long-term clinical service objectives.

Integrated segmentation insights that reveal how test type, cancer target, technology, payment source, application, and end user collectively shape adoption and clinical utility

Segmentation analysis highlights the diversity of technological approaches, clinical targets, payment models, and end users that shape multicancer screening pathways. Based on test type, contemporary offerings range from gene panel approaches that target defined genomic regions to laboratory developed tests that are tailored within certified labs, and to liquid biopsy methods that leverage circulating analytes for minimally invasive sampling. Based on cancer type, the screening landscape spans established targets such as breast cancer and colorectal cancer, hematologic malignancies like leukemia, high-burden indications such as lung cancer, broad non-specific multi-organ cancer detection paradigms, and organ-specific targets like prostate cancer.

Based on technology, core platforms include mass spectrometry for proteomic signatures, microarray approaches for targeted genomic profiling, next-generation sequencing for comprehensive genomic and epigenomic interrogation, and polymerase chain reaction techniques for focused, high-sensitivity detection. Based on payment source, funding and access pathways vary with government subsidies that support public health initiatives, out-of-pocket payment for direct-to-consumer or elective services, and private health insurance that evaluates clinical utility and cost-effectiveness criteria. Based on application, offerings cover diagnostic screening for early detection and risk assessment, prognostic uses such as patient monitoring, therapy selection, and treatment efficacy assessment, and research applications including biomarker discovery and genetic research. Based on end user, deployment spans ambulatory surgical centers, diagnostic centers, hospitals, research institutions, and specialty clinics, each with distinct operational constraints, specimen logistics, and reporting requirements. Together, these segmentation lenses underscore the need for tailored evidence generation, commercial strategies, and implementation pathways that align with the intended use case and stakeholder expectations.

Comparative regional insights highlighting how regulatory frameworks, payer models, and healthcare infrastructure drive differentiated adoption pathways across global regions

Regional dynamics exert a pronounced influence on adoption pathways, regulatory expectations, and payer engagement for multicancer screening programs. In the Americas, mature healthcare infrastructures, active private payer markets, and strong translational research networks create an environment where commercial pilots and commercial models can advance rapidly, while regulatory oversight and reimbursement discussions focus on demonstrating clinical utility and care pathway integration. In Europe, Middle East & Africa, regulatory harmonization initiatives, variable reimbursement environments, and diverse healthcare delivery settings require adaptable evidence strategies, localized health economic models, and targeted stakeholder engagement to secure uptake.

In the Asia-Pacific region, rapid investments in sequencing capacity, growing public health screening initiatives, and expanding clinical trial activity are driving a dynamic landscape where both domestic innovators and global players pursue partnership models. Each region presents distinct operational considerations: supply chain logistics and laboratory capacity differ across geographies, payer frameworks range from public program-driven funding to mixed private-public arrangements, and clinician awareness and care pathways vary by local practice patterns. Consequently, commercial and clinical strategies must be regionally calibrated to address regulatory nuance, reimbursement pathways, and operational readiness while leveraging local research collaborations to accelerate evidence generation.

How collaboration, platform differentiation, and evidence-driven positioning are shaping competitive strategies and commercial pathways among diagnostic developers and laboratories

Competitive dynamics in the multicancer screening arena are characterized by a mix of established diagnostic manufacturers, specialized clinical laboratories, and nimble biotechnology startups pursuing differentiated scientific approaches. Many established players are expanding assay portfolios and forging partnerships with clinical networks to validate broader screening applications, while specialized laboratories are refining workflow integration and accreditation to support laboratory-developed tests with rapid iteration. Startups often focus on unique biomarker platforms, novel bioinformatics, or sample collection innovations that address specific gaps in sensitivity, specificity, or usability.

Strategic activity increasingly centers on collaboration: partnerships between technology providers and large laboratory networks enable access to diverse clinical specimens and pragmatic validation pathways, while alliances with academic centers facilitate translational studies and clinical utility evidence. In addition, contract development and manufacturing relationships help firms scale assay production, and collaborations with health systems support pilot implementations that test real-world clinical pathways. Across these dynamics, robustness of evidence, regulatory clarity, and the ability to integrate into clinical workflows remain primary differentiators that influence adoption trajectories and commercial positioning.

Practical, evidence-focused recommendations for developers, laboratories, and health systems to accelerate credible adoption and operational resilience in multicancer screening

Industry leaders can accelerate responsible adoption of multicancer screening by aligning product development with clear clinical use cases, prioritizing analytic rigor, and engaging early with payers and providers. First, define targeted clinical pathways that specify how a positive screening result will be triaged, what confirmatory diagnostics are required, and how follow-up care will be coordinated; clarity on downstream actions strengthens clinical utility arguments. Second, invest in analytical validation and reproducibility across diverse specimen types and demographic cohorts to reduce variability and build clinician confidence. Third, initiate payer dialogues early and develop health economic models that reflect realistic care pathways and patient journeys to inform reimbursement negotiations.

Operationally, leaders should pursue supply chain diversification and quality-controlled manufacturing to mitigate tariff and logistics risks while ensuring consistent test availability. In parallel, prioritize interoperable reporting formats and EHR integration to facilitate clinical decision support and reduce friction in provider workflows. From a commercialization perspective, pilot programs with integrated care partners, accompanied by pragmatic outcome measurement, provide actionable evidence that accelerates adoption. Finally, cultivate transparent communication with regulators and clinical societies to align on evidence thresholds and appropriate use cases, enabling scalable and clinically responsible deployment.

A rigorous mixed-methods research framework combining expert interviews, peer-reviewed evidence, regulatory review, and data triangulation to validate multicancer screening insights

The research approach combined multi-source evidence collection, expert validation, and iterative synthesis to produce balanced, actionable insights. Primary research included structured interviews with clinicians, laboratory directors, health economists, and payers to capture operational constraints, evidence expectations, and decision drivers across clinical settings. Secondary research drew on peer-reviewed literature, clinical trial registries, regulatory filings, and publicly available guidance from health technology assessment bodies to map technological capabilities and policy trends. Data triangulation was used to reconcile differing perspectives and to identify consistent signals across sources.

Analytical rigor was ensured by cross-checking technical claims against independent validation studies and by assessing operational feasibility through conversations with laboratory operators and supply chain experts. Key limitations and evidence gaps were explicitly characterized to inform future research priorities. Throughout the methodology, ethical considerations and data privacy practices guided the handling of any proprietary or patient-level information, and quality assurance steps were applied to maintain accuracy and credibility in the synthesis of findings.

Concluding synthesis emphasizing evidence alignment, operational readiness, and multi-stakeholder collaboration as prerequisites for responsible multicancer screening adoption

Multicancer screening is at an inflection point where technical maturity, clinical integration needs, and evolving payer perspectives converge to shape near-term trajectories. While technological advances are enabling broader and less invasive detection capabilities, sustainable adoption depends on demonstrable clinical pathways, interoperable reporting, and aligned reimbursement approaches. Stakeholders that pursue clear use case definition, robust validation across diverse cohorts, and pragmatic collaborations with care networks will be best positioned to translate innovation into measurable clinical benefit.

Looking ahead, the focus will be on closing evidence gaps around clinical utility, refining operational models to support scalable testing, and building resilient supply chains that accommodate changing trade and procurement landscapes. By emphasizing transparency in performance, fostering multi-stakeholder engagement, and investing in interoperable systems, the field can progress toward screening programs that deliver earlier detection, more personalized care, and improved outcomes for patients while ensuring sustainable implementation within health systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing adoption of AI-driven liquid biopsy assays for early multicancer detection
  • 5.2. Regulatory approval pathways shaping commercialization of next-generation multicancer screening tests
  • 5.3. Rising investment in cfDNA methylation panels enhancing sensitivity and specificity of tests
  • 5.4. Partnerships between diagnostic labs and technology firms accelerating multicancer screening innovation
  • 5.5. Expansion of direct-to-consumer multicancer screening kits enabling at-home sample collection for early diagnosis
  • 5.6. Integration of electronic health records data with screening results to support personalized cancer risk models
  • 5.7. Emergence of value-based reimbursement models influencing adoption of multicancer screening in health systems
  • 5.8. Focus on underserved populations driving development of accessible multicancer detection programs in low-income regions

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Multicancer Screening Market, by Test Type

  • 8.1. Gene Panel
  • 8.2. Laboratory Developed Test
  • 8.3. Liquid Biopsy

9. Multicancer Screening Market, by Cancer Type

  • 9.1. Breast Cancer
  • 9.2. Colorectal Cancer
  • 9.3. Leukemia
  • 9.4. Lung Cancer
  • 9.5. Non-Specific Multi-Organ Cancer
  • 9.6. Prostate Cancer

10. Multicancer Screening Market, by Technology

  • 10.1. Mass Spectrometry
  • 10.2. Microarray
  • 10.3. Next - Generation Sequencing
  • 10.4. Polymerase Chain Reaction

11. Multicancer Screening Market, by Payment Source

  • 11.1. Government Subsidies
  • 11.2. Out-of-Pocket Payment
  • 11.3. Private Health Insurance

12. Multicancer Screening Market, by Application

  • 12.1. Diagnostic Screening
    • 12.1.1. Early Detection
    • 12.1.2. Risk Assessment
  • 12.2. Prognostics
    • 12.2.1. Patient Monitoring
    • 12.2.2. Therapy Selection
    • 12.2.3. Treatment Efficacy Assessment
  • 12.3. Research Applications
    • 12.3.1. Biomarker Discovery
    • 12.3.2. Genetic Research

13. Multicancer Screening Market, by End User

  • 13.1. Ambulatory Surgical Centers
  • 13.2. Diagnostic Centers
  • 13.3. Hospitals
  • 13.4. Research Institutions
  • 13.5. Specialty Clinics

14. Multicancer Screening Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Multicancer Screening Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Multicancer Screening Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. ANPAC Bio-Medical Science Co., Ltd.
    • 17.3.2. Burning Rock Biotech Limited
    • 17.3.3. Caris Life Sciences
    • 17.3.4. Coyne Medical Ltd.
    • 17.3.5. Delfi Diagnostics, Inc.
    • 17.3.6. Elypta AB
    • 17.3.7. EpiCypher, Inc.
    • 17.3.8. Epigenomics AG
    • 17.3.9. Exact Sciences Corporation
    • 17.3.10. Foundation Medicine, Inc.
    • 17.3.11. Freenome Holdings, Inc.
    • 17.3.12. Fulgent Genetics, Inc.
    • 17.3.13. Gene Solutions
    • 17.3.14. Grail, LLC by Illumina, Inc.
    • 17.3.15. Guangzhou AnchorDx Medical Co., Ltd.
    • 17.3.16. Guardant Health, Inc.
    • 17.3.17. Invitae Corporation
    • 17.3.18. Laboratory Corporation of America Holdings
    • 17.3.19. Lucence Health Inc.
    • 17.3.20. Micronoma, Inc.
    • 17.3.21. MiRXES Pte Ltd.
    • 17.3.22. Myriad Genetics, Inc.
    • 17.3.23. Natera, Inc.
    • 17.3.24. Naveris, Inc.
    • 17.3.25. NeoGenomics Laboratories
    • 17.3.26. OneTest
    • 17.3.27. Siemens Healthineers AG
    • 17.3.28. StageZero Life Sciences. Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MULTICANCER SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. MULTICANCER SCREENING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. MULTICANCER SCREENING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. MULTICANCER SCREENING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL MULTICANCER SCREENING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL MULTICANCER SCREENING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GENE PANEL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GENE PANEL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GENE PANEL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GENE PANEL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GENE PANEL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GENE PANEL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LABORATORY DEVELOPED TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LABORATORY DEVELOPED TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LABORATORY DEVELOPED TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LABORATORY DEVELOPED TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LABORATORY DEVELOPED TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LABORATORY DEVELOPED TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LIQUID BIOPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LIQUID BIOPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LIQUID BIOPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LIQUID BIOPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BREAST CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LEUKEMIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LEUKEMIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LUNG CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY NON-SPECIFIC MULTI-ORGAN CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY NON-SPECIFIC MULTI-ORGAN CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY NON-SPECIFIC MULTI-ORGAN CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY NON-SPECIFIC MULTI-ORGAN CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY NON-SPECIFIC MULTI-ORGAN CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY NON-SPECIFIC MULTI-ORGAN CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY MICROARRAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY MICROARRAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY NEXT - GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY NEXT - GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY NEXT - GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY NEXT - GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY NEXT - GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY NEXT - GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GOVERNMENT SUBSIDIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GOVERNMENT SUBSIDIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GOVERNMENT SUBSIDIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GOVERNMENT SUBSIDIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GOVERNMENT SUBSIDIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GOVERNMENT SUBSIDIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY OUT-OF-POCKET PAYMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY OUT-OF-POCKET PAYMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY OUT-OF-POCKET PAYMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY OUT-OF-POCKET PAYMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY OUT-OF-POCKET PAYMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY OUT-OF-POCKET PAYMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PRIVATE HEALTH INSURANCE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PRIVATE HEALTH INSURANCE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PRIVATE HEALTH INSURANCE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PRIVATE HEALTH INSURANCE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PRIVATE HEALTH INSURANCE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PRIVATE HEALTH INSURANCE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY EARLY DETECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY EARLY DETECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY EARLY DETECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY EARLY DETECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY EARLY DETECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY EARLY DETECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RISK ASSESSMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RISK ASSESSMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RISK ASSESSMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RISK ASSESSMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RISK ASSESSMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RISK ASSESSMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PATIENT MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PATIENT MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PATIENT MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PATIENT MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PATIENT MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PATIENT MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY THERAPY SELECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY THERAPY SELECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY THERAPY SELECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY THERAPY SELECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY THERAPY SELECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY THERAPY SELECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TREATMENT EFFICACY ASSESSMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TREATMENT EFFICACY ASSESSMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TREATMENT EFFICACY ASSESSMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TREATMENT EFFICACY ASSESSMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TREATMENT EFFICACY ASSESSMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TREATMENT EFFICACY ASSESSMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GENETIC RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GENETIC RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GENETIC RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GENETIC RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GENETIC RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GENETIC RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2025-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 246. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2025-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2025-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 266. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 268. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 270. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPE MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE MULTICANCER SCREENING MARK